DEZIMA PHARMA
Dezima Pharma B.V. develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia. The company was founded in 2012 and is based in Naarden, the Netherlands.
DEZIMA PHARMA
Industry:
Biotechnology Therapeutics
Founded:
2012-01-01
Address:
Naarden, Noord-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.dezimapharma.com
Total Employee:
10001+
Status:
Closed
Contact:
+31 35 699 3000
Email Addresses:
[email protected]
Total Funding:
14.2 M EUR
Technology used in webpage:
SPF Google Font API PHP CenturyLink Savvis
Founder
Investors List
BioGeneration Ventures
BioGeneration Ventures investment in Venture Round - Dezima Pharma
Forbion Capital Partners
Forbion Capital Partners investment in Venture Round - Dezima Pharma
New Science Ventures
New Science Ventures investment in Venture Round - Dezima Pharma
Official Site Inspections
http://www.dezimapharma.com
- Host name: 63.128.150.233
- IP address: 63.128.150.233
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Dezima Pharma" on Search Engine
Dezima Pharma - Crunchbase Company Profile & Funding
Organization. Dezima Pharma. Connect to CRM. Summary Financials People Technology Signals & News. Dezima Pharma develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia. Acquired by. Amgen. Naarden, Noord …See details»
Amgen agrees to buy Dutch firm Dezima Pharma in $1.55bn deal
Sep 17, 2015 Amgen has entered a definitive acquisition agreement with Dutch biotechnology firm Dezima Pharma for $1.55bn. Free Report. 2022: So far In Venture …See details»
Amgen To Acquire Privately-Held Dezima Pharma| Amgen
THOUSAND OAKS, Calif. and NAARDEN, Netherlands, Sept. 16, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Dezima Pharma B.V. (Dezima) today announced that the …See details»
Amgen snaps up Dutch biotech Dezima for $1.55 billion
Sep 16, 2015 Dive Brief: Dezima Pharma, which is located in the Netherlands, develops treatments for dyslipidemia. Dezima was founded three years ago and is headquartered …See details»
Amgen To Acquire Privately-Held Dezima Pharma
Sep 17, 2015 Amgen and Dezima Pharma B.V. have announced that the companies have entered into a definitive acquisition agreement under which Amgen will acquire Dezima, …See details»
Amgen To Acquire Privately-Held Dezima Pharma - Pharmacy …
Sep 16, 2015 Amgen. (NASDAQ:AMGN) and. Dezima Pharma B.V. (Dezima) today announced that the companies have entered into a definitive acquisition agreement …See details»
Amgen to Acquire Dezima Pharma, Strikes Deal with Xencor
Sep 17, 2015 Amgen announced that it has entered into a definitive agreement to acquire Dezima Pharma B.V. – a privately held Dutch biotech company, focused on developing …See details»
Amgen Acquires Dezima Pharma, Partners with Xencor
Amgen and Dezima Pharma B.V. have entered into an acquisition agreement under which Amgen will acquire Dezima, a privately-held, Netherlands-based biotechnology company …See details»
Amgen acquires Forbion portfolio company Dezima Pharma
Sep 17, 2015 Forbion Capital Partners’ portfolio company, Dezima Pharma, a biotechnology company developing innovative drugs to treat dyslipidemic patients …See details»
Amgen to buy Dezima Pharma for US$300m in cash
Sep 16, 2015 Amgen is to buy Dezima Pharma, a privately-held, Netherlands-based biotechnology company developing treatments for dyslipidemia, in a move that will …See details»
Amgen kills off CETP inhibitor after seeing Merck data
Oct 26, 2017 Amgen has scrapped development of the CETP inhibitor it acquired in its $1.55 billion takeover of Dezima. The move sees AMG 899 join CETP inhibitors from Eli …See details»
NewAmsterdam Pharma B.V. acquired Dezima Pharma B.V. from …
August 24, 2020. NewAmsterdam Pharma B.V. acquired Dezima Pharma B.V. from Amgen Inc. (NasdaqGS:AMGN) in April 2020. The transaction includes all rights for obicetrapib …See details»
A new biotech forms to revive Amgen's old heart drug
Published Aug. 26, 2020. Ben Fidler Senior Editor. Amgen Inc. Dive Brief: Amgen has licensed out an experimental heart disease drug, obicetrapib, to a newly formed biotech …See details»
SEC.gov
On April 9, 2020, NewAmsterdam Pharma entered into a purchase agreement with Amgen (the “ 2020 SPA ”), to acquire all of the outstanding share capital of NewAmsterdam …See details»
Amgen to acquire privately-held Dezima Pharma
Sep 16, 2015 Amgen (NASDAQ:AMGN) and Dezima Pharma B.V. (Dezima) today announced that the companies have entered into a definitive acquisition agreement …See details»
NewAmsterdam Pharma Acquires Obicetrapib from Amgen
Aug 25, 2020 In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (formerly AMG 899, now TA-8995) a selective …See details»
Dezima Pharma | BioGeneration Ventures
Portfolio. Dezima Pharma develops a best in class CETP inibitor for the treatment of cardiovascular disease. DEzima Pharma was acquired by Amgen in 2015. Year 2012. …See details»
NewAmsterdam Pharma Completes $196M (€160M) Series A …
Jan 14, 2021 Naarden, the Netherlands, January 14, 2021 – NewAmsterdam Pharma (NAP), a clinical stage company focused on the research and development of …See details»
NewAmsterdam bags $196M to resurrect Amgen's discarded …
Jan 14, 2021 Three years later, key players in the Dezima story struck a deal to license the drug at NewAmsterdam Pharma. Now, the company has raised $196 million to find out …See details»
Amgen Inc. completed the acquisition of Dezima Pharma B.V.
Oct 13, 2015 Amgen Inc. completed the acquisition of Dezima Pharma B.V. from Forbion Capital Fund II, L.P., backed by Forbion Capital Partners, BioGeneration Ventures Fund …See details»